Glypican-3-targeting F(ab′)2 for 89Zr PET of hepatocellular carcinoma

Journal of Nuclear Medicine

Volumn 55, Issue 12, 2014, Pages 2032-2037

  Sham, Jonathan G ^a   Kievit, Forrest M ^a   Grierson, John R ^a   Chiarelli, Peter A ^a   Miyaoka, Robert S ^a   Zhang, Miqin ^b   Yeung, Raymond S ^a   Minoshima, Satoshi ^a   Park, James O ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b University of Washington   (United States)

Author keywords

89Zr; F(ab )2; Glypican 3; Hepatocellular carcinoma (HCC); Positron emission tomography (PET)

Indexed keywords

CELL SURFACE RECEPTOR; DODECYL SULFATE SODIUM; FC RECEPTOR; FICIN; GLYPICAN 3; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; GLYPICAN; IMMUNOGLOBULIN F(AB) FRAGMENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOGENICITY; IN VIVO STUDY; LIVER; LIVER CELL CARCINOMA; MOLECULAR DIAGNOSTICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN TARGETING; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; TUMOR XENOGRAFT; ANIMAL; IMMUNOLOGY; LIVER TUMOR; METABOLISM; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIVER NEOPLASMS; MICE; MICE, NUDE; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING; ZIRCONIUM;

EID: 84915820124     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.145102     Document Type: Article

References (43)

1. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC) a global perspective. J Clin Gastroenterol. 2010;44:239-245.
2. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer website. http://globocan.iarc.fr/Pages/fact-sheets-population.aspx. Accessed October 1, 2014.
3. National Comprehensive Cancer Network. Hepatobiliary Cancers Version 2.2014. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician-gls/pdf/hepatobiliary.pdf. Accessed October 1, 2014.
4. ACR. LI-RADS v2013.1. ACR website. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/LIRADS/lirads v20131.pdf. Accessed September 22, 2014.
5. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther. 2010;10:507-519.
6. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59:638-644.
7. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101:513-523.
8. Golfieri R, Marini E, Bazzocchi A, et al. Small (
9. 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med. 2014;55:799-804.
10. Primus FJ, Bennett SJ, Kim EE, DeLand FH, Zahn MC, Goldenberg DM. Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen. Cancer Res. 1980;40:497-501.
11. Milenic DE, Detrick B, Reynolds JC, Colcher D. Characterization of primate antibody responses to administered murine monoclonal immunoglobulin. Int J Biol Markers. 1990;5:177-187.
12. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039-3051.
13. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med. 2001;42:1519-1527.
14. Britton KE. The development of new radiopharmaceuticals. Eur J Nucl Med. 1990;16:373-385.
15. Wong KJ, Baidoo KE, Nayak TK, Garmestani K, Brechbiel MW, Milenic DE. In vitro and in vivo pre-clinical analysis of a F(ab′)(2) fragment of panitumumab for molecular imaging and therapy of HER1 positive cancers. EJNMMI Res. 2011;1.
16. Stafford JH, Hao G, Best AM, Sun X, Thorpe PE. Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine. PLoS ONE. 2013;8:e84864.
17. 89Zr-trastuzumab-F(ab′)2 uptake in SKBR3 tumor xenografts. Mol Pharm. 2012;9:2995-3002.
18. Ma T, Sun X, Cui L, et al. Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo. J Nucl Med. 2014;55:1002-1007.
19. 89Zr-labeled cG250-F(ab′)2 in head and neck tumors. J Nucl Med. 2010;51:1076-1083.
20. 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer. Nucl Med Commun. 2013;34:1157-1165.
21. Milenic DE, Esteban JM, Colcher D. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J Immunol Methods. 1989;120:71-83.
22. Yokota T, Milenic DE,Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402-3408.
23. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2-5.
24. Wahl RL, Parker CW, Philpott GW. Improved radioimaging and tumor localization with monoclonal F(ab′)2. J Nucl Med. 1983;24:316-325.
25. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res. 1986;46:3969-3978.
26. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
27. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
28. 89Zr-labeled panitumumab. J Nucl Med. 2012;53:113-120.
29. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220-233.
30. Elgqvist J, Andersson H, Jensen H, et al. Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. J Oncol. 2010;2010:394913.
31. Wayner EA, Hoffstrom BG. Development of monoclonal antibodies to integrin receptors. Methods Enzymol. 2007;426:117-153.
32. Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
33. Gage GJ, Kipke DR, Shain W. Whole animal perfusion fixation for rodents. J Vis Exp. 2012;65:e3564.
34. Rousseaux J, Rousseaux-Prevost R, Bazin H. Optimal conditions for the preparation of Fab and F(ab′)2 fragments from monoclonal IgG of different rat IgG subclasses. J Immunol Methods. 1983;64:141-146.
35. Mariani M, Camagna M, Tarditi L, Seccamani E. A new enzymatic method to obtain high-yield F(ab)2 suitable for clinical use from mouse IgGl. Mol Immunol. 1991;28:69-77.
36. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991;51:6363-6371.
37. 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread. J Nucl Med. 2014;55:708-709.
38. Zhang Y, Hong H, CaiW. PET tracers based on zirconium-89. Curr Radiopharm. 2011;4:131-139.
39. 18F-labeling of biomolecules for immuno-positron emission tomography. Mol Imaging. 2011;10:168-176.
40. Rolleman EJ, Kooij PP, de Herder WW, Valkema R, Krenning EP, de Jong M. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging. 2007;34:1854-1860.
41. D'Antonio A, Caleo A, Caleo O, Addesso M, Boscaino A. Hepatocellular carcinoma metastatic to the kidney mimicking renal oncocytoma. Hepatobiliary Pancreat Dis Int. 2010;9:550-552.
42. Vegt E, Wetzels JF, Russel FG, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med. 2006;47:432-436.
43. Zhu AX, Gold PJ, El-Khoueiry AB, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013;19:920-928.